• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Psychiatry

Xanomeline-trospium treatment showed improvement in patients with schizophrenia

byRicha SharmaandHarsh Shah
February 27, 2021
in Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Xanomeline-trospium treatment showed a greater reduction in the degree of psychosis in patients with schizophrenia compared to placebo.

2. Patients treated with xanomeline-trospium experienced adverse events such as constipation and nausea but no increase in the incidence of extrapyramidal symptoms.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Current medications, primarily dopamine-antagonists, are used to treat schizophrenia. These medications cause side effects including metabolic disturbances leading to patients withdrawing from prescribed dosing. However, little is known about muscarinic cholinergic receptor agonists and peripheral antagonists as treatments for schizophrenia. As such, the trial examined the safety and efficacy of a combination treatment of xanomeline, a muscarinic receptor agonist, and trospium, a peripherally restricted muscarinic receptor antagonist. Patients receiving the treatment displayed a lower positive and negative syndrome scale (PANSS) score at the end of the study, which indicated this treatment is effective in patients with poor functional status. However, the study resulted in adverse events which were common in both study groups. The study was limited by a small number of study participants resulting in a low power value. Moreover, the study was conducted over a short period of time with no long-term follow-up. Nonetheless, this study’s results are significant, and its findings highlight the xanomeline-trospium combination treatment to be effective in patients with schizophrenia.

Click to read the study in NEJM

Relevant Reading: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multiepisode schizophrenia: a systematic review and network meta-analysis

In-Depth [randomized controlled trial]: This phase 2, double-blind study enrolled 182 participants across 12 hospitals in the United States. Participants between 18 and 60 years of age diagnosed with schizophrenia, a PANSS baseline score of 80 or more, and an episode of acute exacerbation or relapse of psychosis were enrolled into the study. Participants with a history of treatment resistance to antipsychotic medications were excluded from the study. Patients were randomized in a 1:1 ratio to xanomeline-trospium or placebo, respectively. The primary endpoint of the study was a change in the PANSS score from baseline at week five. The study results displayed a mean change of -17.4 points in the treatment group and -5.9 points in the placebo group (least-square means difference, -11.6 points; 95% confidence interval [CI], -16.1 to -7.1; P<0.001). Common adverse events included constipation, nausea, xerostomia, dyspepsia, and vomiting (treatment group, 54%; placebo group, 43%). Overall, the study showed a xanomeline-trospium combination treatment for schizophrenia shows was efficacious; however, further investigation needs to be conducted for the safety of the treatment.

RELATED REPORTS

Majority of long-acting injectable and oral antipsychotics are similar in efficacy for schizophrenia maintenance therapy

Vitamin D supplementation does not improve mental outcomes in adults with early psychosis

Wellness Check: Nutrition

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: muscarinic cholinergic receptor agonistperipheral antagonistPsychosisschizophreniaxanomeline-trospium
Previous Post

Idecabtagene vicleucel showed a response in pre-treated multiple myeloma

Next Post

Relugolix combination therapy led to reduction in uterine fibroid symptoms

RelatedReports

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Chronic Disease

Majority of long-acting injectable and oral antipsychotics are similar in efficacy for schizophrenia maintenance therapy

March 15, 2022
Multiple opioid prescriptions associated with higher hospital admissions
Psychiatry

Vitamin D supplementation does not improve mental outcomes in adults with early psychosis

February 22, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

February 17, 2022
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Chronic Disease

Vitamin D supplementation not supported to treat first-episode psychosis

February 22, 2022
Next Post
Simvastatin associated with slowed fibroid growth in mice

Relugolix combination therapy led to reduction in uterine fibroid symptoms

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine Rewind March 1, 2021

Adolescent mothers in protective care more likely to have their children placed in care

COVID-19 lockdowns associated with increased quiet time and less spoken communication for children with cochlear implants

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.